Unknown

Dataset Information

0

Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients.


ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have become a high-profile regimen for malignancy recently. However, only a small subpopulation obtains long-term clinical benefit. How to select optimal patients by reasonable biomarkers remains a hot topic.

Methods

Paired tissue samples and blood samples from 51 patients with advanced malignancies were collected for correlation analysis. Dynamic changes in blood PD-L1 (bPD-L1) expression, including PD-L1 mRNA, exosomal PD-L1 (exoPD-L1) protein and soluble PD-L1 (sPD-L1), were detected after 2 months of ICIs treatment in advanced non-small-cell lung cancer (NSCLC) patients. The best cutoff values for progression-free survival (PFS) and overall survival (OS) of all three biomarkers were calculated with R software.

Results

In 51 cases of various malignancies, those with positive tissue PD-L1 (tPD-L1) had significantly higher PD-L1 mRNA than those with negative tPD-L1. In 40 advanced NSCLC patients, those with a fold change of PD-L1 mRNA ≥ 2.04 had better PFS, OS and best objective response (bOR) rate. In addition, a fold change of exoPD-L1 ≥ 1.86 was also found to be associated with better efficacy and OS in a cohort of 21 advanced NSCLC cases. The dynamic change of sPD-L1 was not associated with efficacy and OS. Furthermore, the combination of PD-L1 mRNA and exoPD-L1 could screen better patients for potential benefit from ICIs treatment.

Conclusion

There was a positive correlation between bPD-L1 and tPD-L1 expression. Increased expression of PD-L1 mRNA, exoPD-L1, or both in early stage of ICIs treatment could serve as positive biomarkers of efficacy and OS in advanced NSCLC patients.

SUBMITTER: Yang Q 

PROVIDER: S-EPMC8085403 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

altmetric image

Publications

Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients.

Yang Qiao Q   Chen Mingjing M   Gu Jiaoyang J   Niu Kai K   Zhao Xianlan X   Zheng Linpeng L   Xu Zihan Z   Yu Yongxin Y   Li Feng F   Meng Lingxin L   Chen Zhengtang Z   Zhuo Wenlei W   Zhang Luping L   Sun Jianguo J  

Frontiers in immunology 20210416


<h4>Background</h4>Immune checkpoint inhibitors (ICIs) have become a high-profile regimen for malignancy recently. However, only a small subpopulation obtains long-term clinical benefit. How to select optimal patients by reasonable biomarkers remains a hot topic.<h4>Methods</h4>Paired tissue samples and blood samples from 51 patients with advanced malignancies were collected for correlation analysis. Dynamic changes in blood PD-L1 (bPD-L1) expression, including PD-L1 mRNA, exosomal PD-L1 (exoPD-  ...[more]

Similar Datasets

| S-EPMC7584369 | biostudies-literature
| S-EPMC5641120 | biostudies-literature
| S-EPMC7747768 | biostudies-literature
| S-EPMC9806143 | biostudies-literature
| S-EPMC6400216 | biostudies-literature
| S-EPMC4497957 | biostudies-literature
| S-EPMC6480748 | biostudies-literature
| S-EPMC10054797 | biostudies-literature
| S-EPMC10019757 | biostudies-literature
| S-EPMC9322126 | biostudies-literature